Continuous glucose monitoring measures
Continuous glucose monitoring measures has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Jun 5, 2026: “CGM-Derived Measures in Relation to 10-Year CVD Risk in Adults without Diabetes”.
1 paper studies it2 findingsUpdated
See all 1 papers on continuous glucose monitoring measures
At a glance
The findings reach people, from one lab or study. 1 lab.
“Higher 2-h post-MMTT glucose and CGM measures (including mean glucose and time >140mg/dL) were associated with higher odds of intermediate/high CVD risk (ORs: 1.21-1.70, all p<0.001)”
None of its findings points the other way.
- 1 lab
- Humans1
What is continuous glucose monitoring measures linked with?
1Studies link continuous glucose monitoring measures with cardiovascular disease.
Cardiovascular disease
upin humans1OR 1.21–1.7
1 study
Cardiovascular disease
upin humans1OR 1.21–1.7
Continuous glucose monitoring measures are associated with cardiovascular disease in humans (adjusted for fasting plasma glucose; PREVENT score log-transformed) (β 0.07–0.16 per 1 SD increase).
“and a higher overall 10-year CVD risk (per 1 SD increase, β:0.07-0.16, all p<0.001)”
Humansadjusted for fasting plasma glucose; PREVENT score log-transformedn = 1,374
CGM-Derived Measures in Relation to 10-Year CVD Risk in Adults without Diabetes
ADA Scientific Sessions 2026 abstract
Continuous glucose monitoring measures are linked with a higher risk of cardiovascular disease in humans (adjusted for fasting plasma glucose) (OR 1.21–1.70).
“Higher 2-h post-MMTT glucose and CGM measures (including mean glucose and time >140mg/dL) were associated with higher odds of intermediate/high CVD risk (ORs: 1.21-1.70, all p<0.001)”
Humansadjusted for fasting plasma glucosen = 1,374
CGM-Derived Measures in Relation to 10-Year CVD Risk in Adults without Diabetes
ADA Scientific Sessions 2026 abstract